Pfizer India
Stock Snapshot
Price Performance
Vista Outlook
Basis of our Recommendation
Pfizer India is navigating a complex landscape marked by strategic product launches and operational efficiencies, which are expected to bolster revenue growth and maintain stable margins. Management's focus on high-growth therapy areas, particularly through the successful introduction of Prevenar-20 and Emblaveo, positions the company favorably in the expanding pharmaceutical market. The partnership with Cipla aims to enhance market penetration in Tier 2 and non-metro regions, potentially increasing market share and revenue streams. Despite facing challenges such as pricing regulations and rising input costs, Pfizer's disciplined capital allocation and strong cash position provide a buffer against these headwinds. Vista's financial outlook reflects a moderate revenue growth trajectory, with margins expected to remain stable, aligning with the company's strategic initiatives. The favorable macro environment, characterized by improving healthcare demand and currency depreciation benefits, further supports Pfizer's growth potential. Over the next 12-24 months, key opportunities include expanding product offerings and leveraging digital tools for enhanced market engagement, while watchpoints include regulatory risks and competitive pressures in the domestic market
Why We Like This Stock
- Successful new product launches, particularly in vaccines and anti-infectives, are expected to drive revenue growth
- Strategic partnership with Cipla enhances market penetration in underserved regions, potentially increasing market share
- Operational efficiencies and cost rationalization efforts are likely to support stable margins
Things To Watch Out For
- Regulatory pricing pressures may constrain profitability and impact revenue growth
- Rising input costs could challenge margin stability in the near term
- Increased competition in the domestic market may pressure pricing strategies and market share
Key Parameters
Financial Snapshot
View Technicals Analysis →| Actuals | Forecast | ||||
|---|---|---|---|---|---|
| FY24 | FY25 | FY26 | FY27 | FY28 | |
| Revenue (Cr.) | 2,193 | 2,281 | 2,520 | 2,555 | 2,738 |
| Profit Before Tax (Cr.) | 741 | 845 | 1,025 | 1,024 | 1,114 |
| PBT Margin | 33.8% | 37.0% | 40.7% | 40.1% | 40.7% |
| Net Profit (Cr.) | 583 | 625 | 754 | 753 | 819 |
| Earnings Per Share | 127.4 | 136.7 | 164.7 | 164.7 | 179.1 |
Analyst Recommendations
| Broker | Recommendation | Target Price | Date |
|---|---|---|---|
| ICICI Securities | ▲ Buy | 6,000 | 29-Jul-2026 |
Company Overview
Show Company Profile
Pfizer Limited engages in manufacturing, marketing, trading, and distribution of pharmaceutical products in India and internationally. It offers therapy area and products, such as vaccines, injectables and anti-infectives, inflammation and immunology, and internal medicine for cardiovascular care, oncology, respiratory, multivitamins and multimineral, neuroscience, women's health, gastroenterology, pain management, and nutrition, addressing. The company also offers anti-infectives services to hospitals and nursing homes. It sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.